178 related articles for article (PubMed ID: 24486587)
1. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.
Kim H; Saka B; Knight S; Borges M; Childs E; Klein A; Wolfgang C; Herman J; Adsay VN; Hruban RH; Goggins M
Clin Cancer Res; 2014 Apr; 20(7):1865-72. PubMed ID: 24486587
[TBL] [Abstract][Full Text] [Related]
2. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
[TBL] [Abstract][Full Text] [Related]
3. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study.
Romano FJ; Guadagno E; Solari D; Borrelli G; Pignatiello S; Cappabianca P; Del Basso De Caro M
J Cell Biochem; 2018 Jun; 119(6):4867-4877. PubMed ID: 29369420
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
5. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
[TBL] [Abstract][Full Text] [Related]
6. ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.
Arts HH; Lynch L; Grafodatskaya D; Eng B; Malloy L; Duck J; White R; Woodside C; Bell K; Zbuk KM; McCready E
Cancer Genet; 2020 Jan; 240():1-4. PubMed ID: 31671381
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer.
Ceylan F; Guven DC; Taban H; Aktepe O; Sahin TK; Kilickap S; Turker A; Hamaloglu E; Karakoc D; Isik A; Akyol A; Yalcin S; Dizdar O
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102091. PubMed ID: 36738855
[TBL] [Abstract][Full Text] [Related]
8. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
Kim JW; Im SA; Kim MA; Cho HJ; Lee DW; Lee KH; Kim TY; Han SW; Oh DY; Lee HJ; Kim TY; Yang HK; Kim WH; Bang YJ
Int J Cancer; 2014 Jan; 134(1):72-80. PubMed ID: 23649938
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.
Pitter KL; Casey DL; Lu YC; Hannum M; Zhang Z; Song X; Pecorari I; McMillan B; Ma J; Samstein RM; Pei IX; Khan AJ; Braunstein LZ; Morris LGT; Barker CA; Rimner A; Alektiar KM; Romesser PB; Crane CH; Yahalom J; Zelefsky MJ; Scher HI; Bernstein JL; Mandelker DL; Weigelt B; Reis-Filho JS; Lee NY; Powell SN; Chan TA; Riaz N; Setton J
J Natl Cancer Inst; 2021 Mar; 113(3):266-273. PubMed ID: 32726432
[TBL] [Abstract][Full Text] [Related]
10. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
11. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
Bueno RC; Canevari RA; Villacis RA; Domingues MA; Caldeira JR; Rocha RM; Drigo SA; Rogatto SR
Ann Oncol; 2014 Jan; 25(1):69-75. PubMed ID: 24285016
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic
Hannan Z; Yu S; Domchek S; Mamtani R; Reiss KA
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33733050
[TBL] [Abstract][Full Text] [Related]
13. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.
Ji W; Zheng K; Song B; Qin A; Chandoo A; Shao Z; Bi J; Yang X; Jin G; Shen X
Pancreatology; 2019 Jul; 19(5):751-759. PubMed ID: 31221523
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of associations between ATM Asp1853Asn and TP53 Arg72Pro polymorphisms and adverse effects of cancer radiotherapy.
Su M; Yin ZH; Wu W; Li XL; Zhou BS
Asian Pac J Cancer Prev; 2014; 15(24):10675-81. PubMed ID: 25605158
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms.
Hustinx SR; Fukushima N; Zahurak ML; Riall TS; Maitra A; Brosens L; Cameron JL; Yeo CJ; Offerhaus GJ; Hruban RH; Goggins M
Cancer Biol Ther; 2005 May; 4(5):596-601. PubMed ID: 15908786
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Clinicopathologic Characterization of
Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer.
Xun J; Ohtsuka H; Hirose K; Douchi D; Nakayama S; Ishida M; Miura T; Ariake K; Mizuma M; Nakagawa K; Morikawa T; Furukawa T; Unno M
BMC Cancer; 2023 Sep; 23(1):835. PubMed ID: 37674118
[TBL] [Abstract][Full Text] [Related]
19. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
20. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
Tascilar M; Skinner HG; Rosty C; Sohn T; Wilentz RE; Offerhaus GJ; Adsay V; Abrams RA; Cameron JL; Kern SE; Yeo CJ; Hruban RH; Goggins M
Clin Cancer Res; 2001 Dec; 7(12):4115-21. PubMed ID: 11751510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
